Bli medlem
Bli medlem

Du är här




GHENT, Belgium, 23 April 2014 - Ablynx[Euronext Brussels: ABLX]

today announced, in conformity with Title II of the Law of 2 May 2007 and the
Royal Decree of 14 February 2008, that an additional 85,098 common shares
have been issued by the Company in exchange for €451,598.59 as the result of
the exercise of warrants by some employees and consultants of the Company.

As a result of this transaction, Ablynx now has 49,083,327 shares outstanding.

About Ablynx

Ablynxis a biopharmaceutical company engaged in the discovery and development
ofNanobodies®, a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately30 programmes in the pipelineand seven Nanobodies at
clinical development stage. Ablynx has ongoing research collaborations and
significant partnerships with major pharmaceutical companies including
AbbVie, Boehringer Ingelheim, Merck&Co, Merck Serono and Novartis. The
Company is headquartered in Ghent, Belgium. More information can be found

For more information, please contact


Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03

Follow us on Twitter @AblynxABLX

Ablynx media relations
Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 203 709 5700

pdf version of the press release


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.